Nanox Imaging Partners with Adriamed for Nanox.ARC System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Nanox Imaging announced a new collaboration with Adriamed d.o.o. Beograd, a Belgrade-based medical device distributor serving healthcare providers across Southeast Europe, and part of the Adriamed Group. Under the terms of the agreement, Adriamed becomes Nanox's exclusive partner for the Nanox.ARC system and related services in the region, overseeing all aspects of marketing, distribution, installation, and support.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NNOX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NNOX
Wall Street analysts forecast NNOX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NNOX is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.820
Low
7.00
Averages
7.00
High
7.00
Current: 2.820
Low
7.00
Averages
7.00
High
7.00
About NNOX
Nano-X Imaging Ltd is an Israel-based company that develops a digital X-ray source enabling a cost reduction of imaging systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rapid Growth in Cardiac AI Diagnostics Market
- Market Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-native precision, particularly due to the rising demand for heart monitoring in cancer treatments.
- Rise of Cardiac AI Diagnostics: The cardiac AI diagnostics sector hit $2.22 billion in 2026, driven by the urgent need for continuous imaging to monitor heart dysfunction, enhancing the company's competitive edge in the medical technology market.
- Strategic Partnership Enhances Value: Ventripoint's collaboration with Summit Sciences to develop ROI models illustrates how hospitals can achieve cost savings through technological improvements, further solidifying its market position in cardiac care.
- Executive Appointment Fuels Growth: The appointment of David Swetlow as CFO, with extensive experience in medical technology, is expected to accelerate market adoption and revenue growth, driving the execution of the company's commercial strategy.
Continue Reading
Rapid Growth in Cardiac AI Diagnostics Market
- Market Size Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-driven precision, with the cardiac AI diagnostics sector hitting $2.22 billion, reflecting a critical demand for continuous imaging.
- Technological Innovation: VentriPoint Diagnostics is transforming standard 2D ultrasound images into MRI-level 3D heart models, significantly reducing costs and complexity, which is expected to drive rapid growth in its subscription business.
- Surge in Investment Demand: The company recently doubled its private placement from $500,000 to $1 million, with funds allocated for commercialization and market expansion, showcasing strong investor confidence in its technology and market potential.
- Strategic Partnership: VentriPoint's collaboration with Summit Sciences to develop ROI models aims to demonstrate the economic value of its technology to hospitals, further solidifying its market position in medical imaging.
Continue Reading